A large cohort study tracking more than 463,000 U.S. teenagers has found that those who reported cannabis use faced a significantly elevated risk of developing psychotic disorders, including schizophrenia, before age 25. The research, conducted through Kaiser Permanente Northern California, adds to a growing body of evidence that the adolescent brain is especially vulnerable to cannabis exposure, and the strength of the association dwarfs what researchers see in older age groups. With cannabis legalization expanding across the country, the findings carry direct implications for parents, clinicians, and policymakers weighing how to protect young people.
What the Kaiser Permanente Study Found
The study enrolled 463,396 adolescents aged 13 to 17 who were screened for past-year cannabis use between 2016 and 2023. Researchers then followed participants through electronic health records, tracking clinician-diagnosed psychotic, bipolar, depressive, and anxiety disorders up to age 25 or through the end of 2023. The core finding was a set of adjusted hazard ratios showing that teens who used cannabis had a meaningfully higher probability of receiving a psychotic disorder diagnosis than peers who did not use the drug.
The size and design of the study give it unusual weight. Rather than relying on self-reported outcomes or small convenience samples, the Kaiser Permanente team used verified EHR-based diagnoses across a large, integrated health system. That approach reduces recall bias and captures conditions that teens themselves might not volunteer in surveys. The study was published in JAMA Health Forum, and its scale makes it one of the largest U.S.-based analyses to date linking adolescent cannabis exposure to later psychotic illness.
Importantly, the researchers adjusted for a range of potential confounders, including demographic characteristics and co-occurring substance use. Even after those adjustments, cannabis use during adolescence remained strongly associated with later psychotic disorders. While observational designs cannot prove causation, the strength and consistency of the association, combined with evidence from other cohorts, make it increasingly difficult to dismiss the link as a statistical artifact.
Adolescence as a Window of Peak Vulnerability
One of the most striking patterns across recent research is that the cannabis–psychosis link is not uniform across age groups. A separate peer-reviewed analysis in Psychological Medicine reported an age-dependent hazard ratio, estimating that adolescents who used cannabis faced a roughly 11-fold higher risk of psychotic disorder compared with non-users, while the comparable figure in young adults was closer to 1.3. That gap is enormous. It suggests that using cannabis during the teenage years carries a risk profile that is qualitatively different from using it even a few years later.
The biological explanation most often cited in the literature centers on neurodevelopment. The adolescent brain is still pruning synapses and refining prefrontal cortex connections well into the early twenties. During this period, the endocannabinoid system plays a key role in regulating neural maturation. Cannabis, particularly high-THC varieties, can disrupt that system, altering neurotransmitter balance and neural connectivity at a time when circuits involved in reality testing, emotional regulation, and executive function are still being wired.
Epidemiological reviews have long noted that individuals already predisposed to psychosis (because of family history, early developmental complications, or certain genetic variants) appear to face amplified risk from cannabis use. Yet the new cohort data indicate that even teens without known vulnerabilities are not immune. For clinicians, that means the conversation cannot be limited to “high-risk” youth; the window of adolescence itself seems to confer heightened sensitivity to cannabis-related harms.
Young Men Bear the Heaviest Burden
The risk is not evenly distributed by sex. A nationwide Danish register-based cohort analysis covering data from 1972 through 2021 and spanning ages 16 to 49 found that the association between cannabis use disorder and schizophrenia was strongest among young men. Using linked health and registry data, the authors estimated the proportion of schizophrenia cases in this demographic that could theoretically be attributed to cannabis use disorder if all other factors remained constant.
A summary from the National Institute on Drug Abuse highlighted that, in some age bands, cannabis use disorder might account for a sizable share of schizophrenia diagnoses among young males. That framing is notable because it shifts the conversation from individual risk to population-level prevention. If the estimates hold, reducing cannabis use disorder among young men could meaningfully lower the total burden of schizophrenia in a given generation.
These findings also dovetail with clinical observations that young men are more likely to present with first-episode psychosis in the late teens and early twenties, just as heavy cannabis use often peaks. While many factors contribute to this pattern (including social environment, access to care, and other substances), the Danish data suggest that cannabis is not merely a bystander.
High-Potency Products Raise the Stakes
Much of the foundational research on cannabis and psychosis was conducted when average THC concentrations in street cannabis hovered around 4 to 5 percent. Products available in legal dispensaries today routinely exceed 20 percent THC, and concentrates can reach 80 percent or higher. A recent review in a major psychiatric journal concluded that the risk of developing schizophrenia or related psychotic disorders was significantly higher with sustained use of high-THC cannabis compared with lower-potency products.
That shift matters because the products most popular among younger users (vape cartridges, dabs, and distillate-based edibles) tend to deliver large THC doses quickly. The dose–response relationship observed in several cohort studies suggests that both frequency and potency shape risk. For public health agencies, that complicates messaging: telling teens to “use responsibly” assumes a stable product, but the THC content of legal cannabis has climbed steadily since state-level legalization began.
Researchers are also scrutinizing whether early exposure to very high-potency products might accelerate the onset of psychosis in susceptible individuals. While definitive answers will require longer-term follow-up, the convergence of rising potency, declining perception of risk, and increasing adolescent use has many psychiatrists urging a more precautionary stance.
Implications for Policy and Practice
For policymakers, the emerging evidence raises difficult questions about how to regulate a legal market without repeating past mistakes from alcohol and tobacco. Options under discussion include setting upper THC limits for products, restricting marketing that appeals to youth, mandating clearer warning labels about psychosis risk, and dedicating tax revenues to early-intervention mental health services.
Clinicians, meanwhile, are being encouraged to integrate routine cannabis screening into adolescent visits, much as they already do for alcohol. Because many teens perceive cannabis as benign or even therapeutic, conversations need to be frank but nonjudgmental, emphasizing what large cohort studies are actually showing rather than relying on scare tactics. For youth with a family history of psychosis or severe mood disorders, the recommendation is increasingly to avoid cannabis altogether, particularly high-THC forms.
Parents can play a role by staying informed and creating space for open discussion. Pointing to large-scale research, rather than moral arguments, may resonate more with teenagers who see cannabis as just another consumer product. Explaining that the adolescent brain is still under construction, and that heavy cannabis use appears to raise the odds of serious mental illness during this window, can help ground the conversation in science rather than stigma.
Interpreting the Evidence with Care
As with all observational research, it is important to acknowledge limitations. Cannabis use may cluster with other risk factors (such as trauma, social disadvantage, or use of additional substances) that are imperfectly captured in health records. Some adolescents may also begin using cannabis to cope with early, subtle symptoms of mental illness, making it challenging to disentangle cause and effect. Still, when multiple large cohorts, using different methods and populations, converge on a similar association, the argument for a meaningful causal component strengthens.
For readers who want to examine the underlying data more closely, many of the primary studies and related meta-analyses are indexed in federal biomedical databases, and clinicians can customize alerts for new publications through tools like personalized literature dashboards. As the evidence base grows, recommendations for youth, parents, and health systems will likely continue to evolve. For now, the message from the latest cohort work is clear: delaying or avoiding cannabis use during adolescence appears to be one of the more concrete steps young people can take to protect their long-term mental health.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
